Welcome to our dedicated page for QIAGEN N.V. news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on QIAGEN N.V. stock.
QIAGEN N.V. (symbol: QGEN) is a leading global provider of sample-to-insight solutions that transform biological materials into valuable molecular insights. The company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Its assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases from QIAGEN interpret data to report relevant, actionable insights. Automation solutions tie these components together in seamless and cost-effective molecular testing workflows.
QIAGEN serves a diverse customer base of over 500,000 worldwide in sectors such as molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharmaceutical and biotechnology companies), and academia (life sciences research). As of June 30, 2015, the company employed approximately 4,400 people across 35 locations globally. Additional information can be found on their website at http://www.qiagen.com.
QIAGEN's proprietary sample and assay technology enables the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company's revenue is almost evenly split between life sciences and molecular diagnostics applications, with nearly 90% of its revenue derived from consumables and the remaining from instrumentation and related services. The largest portion of QIAGEN's revenue comes from the Americas (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Recent achievements include:
- Q1 2024 net sales of $459 million (-5% at actual rates, -5% at constant exchange rates, CER), with a diluted EPS of $0.36 and an adjusted diluted EPS of $0.46. The net sales at CER of $462 million were ahead of the outlook for at least $455 million CER, and the adjusted diluted EPS of $0.47 CER was ahead of the $0.44 CER outlook.
- Strong operating cash flow rose by 85% to $133 million versus Q1 2023.
- The QCI Secondary Analysis software, integrated with QCI Interpret, facilitates high-throughput secondary analysis of clinical next-generation sequencing data.
- Collaborations aimed at creating novel digital PCR assays to improve DNA analysis in forensics and human identification.
- Introduction of the QIAstat-Dx Respiratory Panel Plus for accurate diagnosis of respiratory infections, capable of generating results in about one hour with minimal hands-on time.
- Enhancements to the QIAGEN Clinical Insight Interpret platform, which has processed over 4 million NGS patient test cases for oncology and hereditary diseases worldwide.
- New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis, complementing the company's existing assay offerings.
QIAGEN continues to innovate and maintain its leading position in the molecular diagnostics and life sciences industries. The company's ongoing efforts to expand its product offerings and enhance its technologies ensure that it remains a trusted partner for researchers and healthcare providers worldwide.
QIAGEN has announced details for a synthetic share repurchase plan to return up to $300 million to shareholders, combining a direct capital repayment with a reverse stock split. The plan follows a similar $300 million repurchase completed in early 2024, totaling $600 million of the company's commitment to return at least $1 billion to shareholders by 2028.
The repurchase terms include consolidating every 36 issued shares into 35 shares, reducing approximately 6.2 million shares from the 223.9 million shares outstanding at end-2024. Shareholders will receive $1.26 per pre-split share. The last trading day for pre-split shares is planned for January 28, 2025, with consolidated shares beginning trading on January 29, 2025, on both NYSE and Frankfurt Stock Exchange under existing ticker symbols.
QIAGEN N.V. (NYSE: QGEN) has announced its schedule for the release of Q4 2024 financial results. The press release will be issued on Wednesday, February 5, after 22:05 Frankfurt time (21:05 London/16:05 New York). A conference call will follow on Thursday, February 6, at 16:00 Frankfurt time (15:00 London/10:00 New York).
Participants can join the conference call through three options: registering for a callback connection, dialing in directly using provided international numbers, or accessing the audio webcast. The conference ID for phone dial-in is 9237018. A replay of the conference call will be made available through a provided webcast link.
QIAGEN (NYSE: QGEN) has announced plans to return up to $300 million to shareholders through a synthetic share repurchase, combining a direct capital repayment with a reverse stock split. This follows a similar $300 million repurchase completed in early 2024, totaling $600 million of the company's commitment to return at least $1 billion to shareholders by the end of 2028 (absent M&A opportunities).
The synthetic repurchase, scheduled for completion in late January 2025, will be executed through a three-step process: increasing the par value of common shares, implementing a reverse stock split, and reducing the par value back to the original level with direct capital repayment to shareholders. This approach aims to deliver faster returns compared to traditional open-market repurchases while enhancing earnings per share (EPS) through reduction in outstanding shares.
QIAGEN (NYSE: QGEN) has announced significant enhancements to its QIAcuity Digital PCR system, enabling simultaneous analysis of up to 12 targets from a single biological sample, more than doubling its previous capability of five targets. This upgrade is achieved through the new QIAcuity Software 3.1 and the launch of the QIAcuity High Multiplex Probe PCR Kit, requiring no hardware changes to existing instruments.
The system has shown strong market adoption with over 2,700 cumulative placements by end of 2024 and citations in more than 550 publications. The enhancement makes lab work more efficient by reducing time, reagent consumption, and sample material usage. The platform integrates partitioning, thermocycling, and imaging into a streamlined workflow, reducing processing times from six to two hours.
The QIAcuity platform is available in one-, four-, and eight-plate versions to accommodate different laboratory sizes and throughput requirements. The technology is particularly valuable for applications in translational research, microbiome analysis, pathogen detection, and cell and gene therapy development.
QIAGEN (NYSE: QGEN) has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, marking the first in a series of gastrointestinal panel tests. The panel covers five key causes of gastrointestinal illness recommended by the IDSA, including four bacteria and Norovirus.
This clearance makes QIAGEN the first company to offer both comprehensive and targeted syndromic gastrointestinal panels, enhancing diagnostic flexibility for healthcare providers. The test delivers results in about one hour with minimal hands-on time.
A second version covering five bacterial pathogens is planned for FDA submission. Additionally, QIAGEN plans to submit its higher-capacity QIAstat-Dx Rise instrument for FDA clearance in early 2025, which can process up to 160 tests daily using eight Analytical Modules.
QIAGEN has partnered with Genomics England to support the Generation Study, a groundbreaking initiative to sequence genomes of 100,000 newborns in England. The study, launched in October 2024, will screen for over 200 treatable conditions that affect approximately 3,000 babies annually in the UK.
Through its Clinical Knowledge Base, QIAGEN will be the exclusive provider of clinically relevant variant content for genes included in the point-of-care sequencing test. The company's knowledge base combines expert manual curation with machine extraction, containing biological content from more than 40 databases and has been used to analyze over 4 million NGS patient test cases globally.
The initiative aims to enable earlier diagnosis and treatment of rare conditions like Metachromatic leukodystrophy (MLD), potentially improving health outcomes for thousands of families through early intervention.
QIAGEN has launched Ingenuity Pathway Analysis (IPA) Interpret, an AI-powered extension designed to enhance the interpretation of complex biological data. The new feature builds upon IPA's extensively curated knowledge base, which has over 50,000 citations, to help researchers understand gene involvement in diseases, biological processes, and drug responses.
IPA Interpret automatically analyzes gene expression datasets, identifying key biological processes, pathways, and networks, presenting results in a shareable web-page format. The tool combines human expertise with AI and Natural Language Processing to ensure reliable data analysis and causal relationships. This launch follows QIAGEN's recent AI initiatives, including an AI-driven biomedical knowledgebase release in early 2024 and AI enhancements to QIAGEN Clinical Insight Interpret in late 2023.
QIAGEN has announced reaching over 1,000 placements of its EZ2 Connect automated sample preparation instrument, contributing to a global installed base exceeding 5,500 EZ series instruments. Launched in 2021, the system automates nucleic acid purification, reducing hands-on time while maintaining high precision.
The company has expanded its portfolio with the launch of EZ2 PowerFecal Pro DNA/RNA Kit for gut microbiome research, requiring only 27 minutes of hands-on time compared to 45+ minutes for similar kits. The comprehensive EZ2 Connect portfolio supports various applications including diagnostics, genomics, cancer research, and forensics, with additional kits planned for 2025.
QIAGEN announced plans to relocate its QIAstat-Dx operations to a new 8,000-square-meter site in Esplugues de Llobregat, Barcelona, set to open in early 2026. The facility will support the entire value chain for the QIAstat-Dx system, which performs syndromic testing for infectious diseases and precision medicine applications. The site will include R&D, manufacturing, sales, marketing, and regulatory operations, featuring digitalized production lines and LEED Platinum certification. The expansion aims to strengthen QIAGEN's diagnostic capabilities and support recent partnerships with Eli Lilly and AstraZeneca. The QIAstat-Dx system currently has FDA clearance for four panels and CE-marking for two panels under IVDR.
QIAGEN has launched two new tools for customizing microbial analysis solutions: a first-of-its-kind Custom dPCR Microbial Assays design tool and QIAseq xHYB Custom Microbial Panels. The dPCR tool enables customized primer and probe design for bacterial, fungal, and viral targets, while the NGS panels allow comprehensive genome coverage for improved microbial detection. These additions complement QIAGEN's existing portfolio of over 700 digital PCR assays for microbial targets, accessible through the GeneGlobe platform. The new tools enhance capabilities in applications ranging from wastewater testing to food production and human pathogen analysis.
FAQ
What is the current stock price of QIAGEN N.V. (QGEN)?
What is the market cap of QIAGEN N.V. (QGEN)?
What does QIAGEN N.V. do?
How many employees does QIAGEN N.V. have?
What are QIAGEN's recent financial achievements?
What industries does QIAGEN serve?
What are QIAGEN’s proprietary technologies?
Where can I find more information about QIAGEN?
What are some of QIAGEN's recent innovations?
How is QIAGEN's revenue split?
Which regions contribute most to QIAGEN's revenue?
What is the QIAstat-Dx Respiratory Panel Plus?
